GlassScriptPhysician profile
Steven Hartford
NPI 1215904099
$5,967.53
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,299 · 2020: $544 · 2021: $344 · 2022: $556 · 2023: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,516.94 | 2019-2023 | |
| Therapeuticsmd, INC. | $246.17 | 2019-2021 | |
| Boston Scientific Corporation | $184.14 | 2022-2023 | Bodyguardian |
| Davol INC. | $151.93 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.18 | 2019-2023 | |
| Hologic Sales and Service, LLC | $98.49 | 2019-2023 | Thinprep 2000 Processor, Aptima |
| Myovant Sciences INC. | $94.94 | 2021-2022 | |
| Pfizer INC. | $86.64 | 2019-2023 | |
| Roche Diagnostics Corporation | $64.86 | 2019 | |
| Allergan, INC. | $58.22 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $54.31 | 2019 | |
| Evofem Biosciences, INC. | $45.58 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $40.39 | 2023 | Myfembree |
| Astellas Pharma US INC | $39.57 | 2023 | Veozah |
| Ascend Therapeutics US, LLC | $34.66 | 2021-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $29.89 | 2021 | |
| Coopersurgical, INC. | $19.31 | 2020 | |
| Mission Pharmacal Company | $17.02 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $16.67 | 2023 | Vivjoa |
| Duchesnay USA Incorporated | $16.03 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.84 | 2021 | |
| Lupin INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hartford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.